TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29206647

Group type: EXPERIMENTAL
Intervention: Acute intravenous sodium loading (hypertonic saline 5 mmol sodium/liter body water for 30 minutes)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic dietary sodium loading (more than 200 mmol/day for eight days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both sodium interventions (acute and chronic)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic dietary sodium loading
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acute intravenous sodium loading
Number of subjects: 12
Study: 27497806

Group type: EXPERIMENTAL
Intervention: Radial approach
Number of subjects: 103

Group type: COMPARATOR
Intervention: Femoral approach
Number of subjects: 103
Study: 24939310

Group type: EXPERIMENTAL
Intervention: 17% EDTA with 2.5% NaOCl for 1 min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 17% EDTA with 2.5% NaOCl for 3 min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 17% EDTA with 2.5% NaOCl for 5 min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 17% EDTA with 2.5% NaOCl for 7 min
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2.5% NaOCl (control group A)
Number of subjects: 25
Study: 22105437

Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Periodontal disease (PD)
Number of subjects: 1453

Group type: EXPERIMENTAL
Intervention: Coexistence of BV and PD
Number of subjects: 1453
Study: 20480060

Group type: EXPERIMENTAL
Intervention: Miswaks fluoridated in 0.1% NaF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Miswaks fluoridated in 0.5% NaF
Number of subjects: 10

Group type: COMPARATOR
Intervention: Brushing with 1 g of F-containing dentifrice (0.32% NaF)
Number of subjects: 10
Study: 18486203

Group type: EXPERIMENTAL
Intervention: H5‐KIDS program (home based intervention)
Number of subjects: 1306
Study: 15966655

Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesive system (Clearfil Protect Bond)
Number of subjects: 35

Group type: COMPARATOR
Intervention: One-step self-etching adhesive system (Xeno III)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 35
Study: 11815513

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10075321

Group type: EXPERIMENTAL
Intervention: Physical training for 4 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: No physical training for 4 months (control)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 34
Study: 8649135

Group type: EXPERIMENTAL
Intervention: GIK with 20 minutes of CPB prior to cardioplegic arrest
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with no GIK and no CPB support
Number of subjects: 20
Study: 2246313

Group type: EXPERIMENTAL
Intervention: Standard antibiotic bowel preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no antibiotic bowel preparation)
Number of subjects: 30
Study: 6118716

Group type: EXPERIMENTAL
Intervention: Fat-modified diet (diet B, 27% energy from fat, P/S 1.0, reduced cholesterol content)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fat-modified diet supplemented with fruit, vegetable, and cereal fibre (diet C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diet providing 40% energy from fat, P/S ratio 1.0 and supplemented by fibre (diet D)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Western reference diet (40% energy from fat, P/S ratio 0.27)
Number of subjects: 12
Study: 6403171

Group type: EXPERIMENTAL
Intervention: Continuous Doppler ultrasound during fetal heart rate monitoring
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 150
Study: 30499065

Group type: EXPERIMENTAL
Intervention: Preference-elicitation instrument (version identified as well accepted)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Four versions of the preference-elicitation instrument
Number of subjects: 200
Study: 30136741

Group type: EXPERIMENTAL
Intervention: Immediate or delayed periodontal treatment (full-mouth non-surgical scaling and root planing, systemic antibiotics, and oral health instructions)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Immediate or delayed periodontal treatment
Number of subjects: 91
Study: 27863480

Group type: EXPERIMENTAL
Intervention: Patient-centered cognitive behavioral therapy intervention group
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard information-only group (control)
Number of subjects: 62
Study: 24262684

Group type: EXPERIMENTAL
Intervention: Prophylactic Bakri balloon immediately following placental delivery
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual surgical/pharmacologic measures to achieve hemostasis
Number of subjects: 52
Study: 22162534

Group type: EXPERIMENTAL
Intervention: GSK1521498 (2, 5, and 10 mg) administered once daily for 10 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK1521498 (10 mg) administered once daily for 10 days
Number of subjects: 0
Study: 20921870

Group type: EXPERIMENTAL
Intervention: Anxious attachment
Number of subjects: 110

Group type: COMPARATOR
Intervention: Care coordinators' reports
Number of subjects: 110
Study: 18386046

Group type: EXPERIMENTAL
Intervention: EBM course in combination with case method learning sessions (CMLSs)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study: 16212575

Group type: EXPERIMENTAL
Intervention: Experimental gingivitis
Number of subjects: 96
Study: 12030591

Group type: EXPERIMENTAL
Intervention: High energy drink (402 kJ)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low energy drink (1 kJ)
Number of subjects: 27
Study: 10025428

Group type: EXPERIMENTAL
Intervention: MRI pattern with hyperintense lateral rim and dorsolateral hypointense signal attenuation on T2-weighted images
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hypointense changes in the putamen
Number of subjects: 90
Study: 7723464

Group type: EXPERIMENTAL
Intervention: Data base approach to assess relative efficacy of alternative therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reconsideration of necessity for RCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality assurance program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recording reasons for therapy selection
Number of subjects: 0
Study: 2107581

Group type: EXPERIMENTAL
Intervention: Combination of a diuretic (clopamide 5 mg), a vasodilator (dihydro‐ergocristine 0.5 mg) and reserpine (0.1 mg) (CDR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methyldopa (MD) plus hydrochlorothiazide (HCT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Compliance
Number of subjects: 18

Group type: COMPARATOR
Intervention: Adverse effects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Patient preference
Number of subjects: 18
Study: 7410745

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: All drugs (Theophylline, Terbutaline, Prednisone)
Number of subjects: 11
Study: 30782027

Group type: COMPARATOR
Intervention: Exercise + Sitting (EX+SIT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Exercise + Breaks (EX+BR)
Number of subjects: 67
Study: 30269276

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 leucovorin (LV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 200 mg/m2 leucovorin (LV)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 500 mg/m2 leucovorin (LV)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0 mg/m2 leucovorin (LV) (untreated)
Number of subjects: 80
Study: 26818098

Group type: EXPERIMENTAL
Intervention: EQ‐5D‐3 L
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: SF‐6D
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: SF‐12
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: SGRQ
Number of subjects: 795
Study: 23954038

Group type: EXPERIMENTAL
Intervention: PID‐C (personalized intervention for depressed patients with COPD)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: PID‐C
Number of subjects: 138
Study: 21923839

Group type: EXPERIMENTAL
Intervention: Any time users of prednisone
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Non-users of prednisone
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Users of prednisone for 30 or more days
Number of subjects: 1051
Study: 19679284

Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 755

Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 755
Study: 17635470

Group type: EXPERIMENTAL
Intervention: Malan radiological sinusitis typing (RST) system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lund‐Mackay (LM) system
Number of subjects: 10
Study: 15026873

Group type: EXPERIMENTAL
Intervention: Multiple stenting
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single stenting
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Single stenting in type C lesions
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (diagnostic coronary angiography)
Number of subjects: 50
Study: 11675056

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (milk-extracted calcium phosphate)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 10322830

Group type: EXPERIMENTAL
Intervention: Modified Sijunzi decoction (MSJZD)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Weimeisu
Number of subjects: 202
Study: 8480058

Group type: EXPERIMENTAL
Intervention: Active group (nicotine chewing gum + group psychotherapy)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo group (placebo chewing gum + group psychotherapy)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Outpatient group (nicotine chewing gum + individual psychotherapy)
Number of subjects: 106
Study: 3039234

Group type: EXPERIMENTAL
Intervention: Low NaCl Group (2 to 7 mEq/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: High NaCl Group (126 mEq/day)
Number of subjects: 6
Study: 30953176

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) protocol (5 min ischemia, repeated 3 times, each separated by 5 min reperfusion) before every training session
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (identical endurance training without IPC)
Number of subjects: 14
Study: 27494634

Group type: EXPERIMENTAL
Intervention: School Asthma Action Program (SAAP)
Number of subjects: 47
Study: 25609231

Group type: EXPERIMENTAL
Intervention: DAIRY (1% fat milk, 1.5% fat yogurt, 34% fat cheese)
Number of subjects: 124

Group type: COMPARATOR
Intervention: CONTROL (fruit and vegetable juice, cashews, and a cookie)
Number of subjects: 124
Study: 23432730

Group type: EXPERIMENTAL
Intervention: Brinzolamide-timolol fixed combination
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 92
Study: 21115134

Group type: COMPARATOR
Intervention: GoLytely (4 L split-dose)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: MiraLAX alone (combined with 64 oz of Gatorade)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: MiraLAX with lubiprostone (24 μg)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: MiraLAX with bisacodyl (10 mg)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: MiraLAX (all groups)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: GoLytely and MiraLAX groups
Number of subjects: 403
Study: 18932058

Group type: EXPERIMENTAL
Intervention: Combination treatment with 500 mg alpha‐tocopherol and 2 g vitamin C for 12 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16676013

Group type: EXPERIMENTAL
Intervention: Mailed orientation program (intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12836023

Group type: EXPERIMENTAL
Intervention: Associative group with predictable damping force based on initial position
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-associative group with unpredictable damping force
Number of subjects: 32
Study: 11342473

Group type: EXPERIMENTAL
Intervention: 2 g/kg IVIG
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 8803738

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 1411634

Group type: COMPARATOR
Intervention: Combination cisplatin and carboplatin plus doxorubicin/hexamethylmelamine/cyclophosphamide
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin (350 mg/m2 on day 1) plus oral cyclophosphamide (100 mg/m2 days 2 to 6)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: High-dose carboplatin (800 mg/m2)
Number of subjects: 341
Study: 3880635

Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30652892

Group type: COMPARATOR
Intervention: Interacting pairs in a visual search task (Experiments 1a and 1b)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interacting individuals in a spatial judgment task (Experiments 2a and 2b)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interacting partners in a surprise memory task (Experiments 3a and 3b)
Number of subjects: 0
Study: 28553750

Group type: EXPERIMENTAL
Intervention: Web-based intervention (Let's Choose Ourselves)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26951379

Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg every 2 weeks)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Fotemustine (75 mg/m² on days 1, 8, and 15, then 100 mg/m² every 3 weeks after a 35-day interval)
Number of subjects: 91
Study: 24702886

Group type: EXPERIMENTAL
Intervention: mannitol
Number of subjects: 20

Group type: COMPARATOR
Intervention: deep inhalation methacholine challenge
Number of subjects: 20
Study: 22999372

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer (Fuji IX GP(®))
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer (Vitremer(®))
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (Sound teeth)
Number of subjects: 35
Study: 20703472

Group type: EXPERIMENTAL
Intervention: Intrasphincteric injection of botulinum toxin (BT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy (LIS)
Number of subjects: 80
Study: 19017911

Group type: EXPERIMENTAL
Intervention: G. biloba (120 mg twice daily)
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study: 16018146

Group type: EXPERIMENTAL
Intervention: Intranasal 17 beta‐estradiol 300 microg daily
Number of subjects: 309
Study: 12144817

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 314

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 314
Study: 10638109

Group type: EXPERIMENTAL
Intervention: nimesulide
Number of subjects: 90

Group type: COMPARATOR
Intervention: piroxicam
Number of subjects: 90
Study: 7804897

Group type: EXPERIMENTAL
Intervention: Chemopreventive agents
Number of subjects: 0
Study: 1553935

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.25 mg, three times a day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3159407

Group type: EXPERIMENTAL
Intervention: diazepam 0.2 mg kg‐1 i.v.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: midazolam 0.05 mg kg‐1 i.v.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: midazolam 0.1 mg kg‐1 i.v.
Number of subjects: 76
Study: 29198539

Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 88
Study: 26152668

Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (N = 18) for 50 hours
Number of subjects: 34

Group type: COMPARATOR
Intervention: Computer games control (N = 16)
Number of subjects: 34
Study: 23448285

Group type: EXPERIMENTAL
Intervention: Behavioural treatment (pelvic floor muscle training, delayed voiding, urge suppression techniques)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Antimuscarinic drug therapy (extended-release oxybutynin)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Behavioural treatment (for those with ≥2 episodes nocturia at baseline)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Antimuscarinic therapy (for those with ≥2 episodes nocturia at baseline)
Number of subjects: 127
Study: 21070382

Group type: EXPERIMENTAL
Intervention: Direct ball attachment incorporation (group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Indirect ball attachment incorporation (group B)
Number of subjects: 45
Study: 18799365

Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: aMDRD
Number of subjects: 38

Group type: COMPARATOR
Intervention: C&G
Number of subjects: 38
Study: 17304525

Group type: EXPERIMENTAL
Intervention: Burch urethropexy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 390
Study: 15490824

Group type: EXPERIMENTAL
Intervention: Bicoherence analysis using statistical tools for thresholding
Number of subjects: 0
Study: 11677204

Group type: EXPERIMENTAL
Intervention: Antibiotics (20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo (20 mg omeprazole twice a day and identical placebos for 1 week)
Number of subjects: 190

Group type: COMPARATOR
Intervention: H. pylori-negative group (open label 20 mg omeprazole twice a day for 1 week)
Number of subjects: 190
Study: 9058440

Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral diet
Number of subjects: 12
Study: 8445307

Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium for 24 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cefotaxime sodium for 7 days
Number of subjects: 60
Study: 3007163

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg b.i.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 10
Study: 29912844

Group type: EXPERIMENTAL
Intervention: Booster dose of IXIARO administered 12 months after primary immunization
Number of subjects: 300

Group type: COMPARATOR
Intervention: No booster dose
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Booster dose of IXIARO
Number of subjects: 300
Study: 26315004

Group type: EXPERIMENTAL
Intervention: Valve setting reduced from 20 cm H2O to 4 cm H2O over 6 months (20-4 group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Fixed valve setting at 12 cm H2O (12 group)
Number of subjects: 68
Study: 24627290

Group type: EXPERIMENTAL
Intervention: Gemigliptin (50 mg once daily) and Metformin (1,000 mg twice a day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Metformin (1,000 mg twice a day)
Number of subjects: 27
Study: 22278162

Group type: EXPERIMENTAL
Intervention: Physical therapy (hot pack, ultrasound therapy, friction massage)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 59
Study: 20357382

Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 18771887

Group type: EXPERIMENTAL
Intervention: TAG endograft
Number of subjects: 234

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Combined morbidity/mortality endpoint (stroke/paralysis/MI/death)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: TAG
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Endovascular group
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Procedure times
Number of subjects: 234
Study: 16364831

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 12456445

Group type: EXPERIMENTAL
Intervention: Tramadol infusion (1 mg/kg loading dose, 0.2 mg/kg/h postoperative infusion)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Morphine PCA alone (control group)
Number of subjects: 69
Study: 10333097

Group type: EXPERIMENTAL
Intervention: Treadmill
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cycle Ergometer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both Treadmill and Cycle Ergometer
Number of subjects: 32
Study: 8619358

Group type: EXPERIMENTAL
Intervention: Iobitridol (Xenetix 350)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Iohexol (Omnipaque)
Number of subjects: 90
Study: 2031819

Group type: EXPERIMENTAL
Intervention: i.v. atropine 0.5 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: i.v. saline 1 ml
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: i.v. lignocaine 3 ml with adrenaline 15 micrograms
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: adrenaline test dose
Number of subjects: 90
Study: 7404171

Group type: EXPERIMENTAL
Intervention: Alveolar lavage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transbronchial biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded radiological evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of transbronchial biopsy, alveolar lavage, and radiography
Number of subjects: 0
Study: 31980506

Group type: EXPERIMENTAL
Intervention: Zinc acetate lozenges (13 mg elemental zinc, taken six times per day for a maximum of 5 days)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Placebo lozenges (sucrose octa-acetate, taken six times per day for a maximum of 5 days)
Number of subjects: 253
Study: 31484629

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11154
Study: 28628688

Group type: EXPERIMENTAL
Intervention: Laser treatment and nutraceutical (Group 2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laser treatment (Group 1)
Number of subjects: 20
Study: 25940727

Group type: EXPERIMENTAL
Intervention: Aggressive suction‐curettage
Number of subjects: 130

Group type: COMPARATOR
Intervention: Open excision
Number of subjects: 130
Study: 23393307

Group type: EXPERIMENTAL
Intervention: Innovative curriculum using trigger videos modeling screening for SDH
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed)
Number of subjects: 36